--- title: "NEOGENOMICS INC (NEO) news: offering and convertible notes" url: "https://aibio.space/companies/neogenomics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NEO offering and convertible notes news: NeoGenomics completes $316.25 million convertible notes offering. NEOGENOMICS INC (NASDAQ: NEO), United States." --- NEO NEOGENOMICS INC NASDAQ · United States # NEOGENOMICS INC (NEO) news NEO offering and convertible notes news Debt Financing · 2026-06-22 ## [NeoGenomics completes $316.25 million convertible notes offering](https://aibio.space/news/neogenomics-completes-316-25-million-convertible-notes-offering/) NeoGenomics completed $316.25 million of 0.75% convertible senior notes due 2032 under an indenture with U.S. Bank Trust Company, National Association, as trustee. It used about $28.7 million of the proceeds on capped calls. ## Latest NEOGENOMICS INC news We have not published a story on NEOGENOMICS INC yet. When there is news, it will appear here. ## NEOGENOMICS INC at a glance - **Ticker**: NEO - **Listing**: NASDAQ - **Country**: United States - **Cash, Sep 30, 2026**: $139.3 million ### Related companies - [EDAP TMS SA](https://aibio.space/companies/edap-tms/) NASDAQ: FOCL - [Ginkgo Bioworks Holdings](https://aibio.space/companies/ginkgo-bioworks/) NYSE: DNA - [VASO](https://aibio.space/companies/vaso/) OTC: VASO - [METTLER TOLEDO INTERNATIONAL INC/](https://aibio.space/companies/mettler-toledo-international/) NYSE: MTD - [Genenta Science S.p.A.](https://aibio.space/companies/genenta-science-s-p-a/) NASDAQ: GNTA - [Beyond Air](https://aibio.space/companies/beyond-air/) NASDAQ: XAIR - [Twist Bioscience](https://aibio.space/companies/twist-bioscience/) NASDAQ: TWST - [Neuraxis, INC](https://aibio.space/companies/neuraxis/) NYSE: NRXS ### Also on NASDAQ - [Acurx Pharmaceuticals](https://aibio.space/companies/acurx-pharmaceuticals/) ACXP - [Zentalis Pharmaceuticals](https://aibio.space/companies/zentalis-pharmaceuticals/) ZNTL - [Corvus Pharmaceuticals](https://aibio.space/companies/corvus-pharmaceuticals/) CRVS - [Inogen](https://aibio.space/companies/inogen/) INGN - [Iovance Biotherapeutics](https://aibio.space/companies/iovance-biotherapeutics/) IOVA - [ARS Pharmaceuticals](https://aibio.space/companies/ars-pharmaceuticals/) SPRY ## NEOGENOMICS INC annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$37.1 million](https://www.sec.gov/Archives/edgar/data/1077183/000107718326000010/) | [$31.2 million](https://www.sec.gov/Archives/edgar/data/1077183/000107718326000010/) | | Net income (loss) | [-$108.0 million](https://www.sec.gov/Archives/edgar/data/1077183/000107718326000010/) | [-$78.7 million](https://www.sec.gov/Archives/edgar/data/1077183/000107718326000010/) | | Cash from operations | [$5.2 million](https://www.sec.gov/Archives/edgar/data/1077183/000107718326000010/) | [$7.0 million](https://www.sec.gov/Archives/edgar/data/1077183/000107718326000010/) | | Cash and equivalents | [$159.6 million](https://www.sec.gov/Archives/edgar/data/1077183/000107718326000079/) | [$367.0 million](https://www.sec.gov/Archives/edgar/data/1077183/000107718326000010/) | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $139.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about NEOGENOMICS INC Has NEOGENOMICS INC raised money recently? Our latest story on this, dated Jun 22, 2026: "NeoGenomics completes $316.25 million convertible notes offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/neogenomics-completes-316-25-million-convertible-notes-offering/). Has NEOGENOMICS INC sold convertible notes? Our latest story on this, dated Jun 22, 2026: "NeoGenomics completes $316.25 million convertible notes offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/neogenomics-completes-316-25-million-convertible-notes-offering/). What is the ticker symbol of NEOGENOMICS INC? NEOGENOMICS INC trades under the ticker NEO on NASDAQ. Where is NEOGENOMICS INC listed? NEOGENOMICS INC is listed on NASDAQ. Which country or territory is NEOGENOMICS INC listed under? Our directory records NEOGENOMICS INC under United States. Does aibio.space cover NEOGENOMICS INC? aibio.space lists NEOGENOMICS INC among 2,820 public biotech companies and publishes its news here as stories appear. Is NEOGENOMICS INC profitable? NEOGENOMICS INC reported a net loss of $108.0 million for the fiscal year ended Dec 31, 2025, and generated $5.2 million of cash from operations, per its annual report to the SEC. How much does NEOGENOMICS INC spend on research and development? $37.1 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does NEOGENOMICS INC have? $139.3 million in cash at Sep 30, 2026, per its 10-Q. What is the latest NEOGENOMICS INC (NEO) stock news? Our latest story on NEOGENOMICS INC, dated Jun 22, 2026: "NeoGenomics completes $316.25 million convertible notes offering". NeoGenomics completed $316.25 million of 0.75% convertible senior notes due 2032 under an indenture with U.S. Bank Trust Company, National Association, as trustee. It used about $28.7 million of the proceeds on capped calls. [Source](https://aibio.space/news/neogenomics-completes-316-25-million-convertible-notes-offering/). How can I follow NEOGENOMICS INC (NEO) news? Press Follow on this page to add NEOGENOMICS INC to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming NEOGENOMICS INC so far, in Debt Financing. ## Investor discussion: NEOGENOMICS INC Members talk about NEOGENOMICS INC (NEO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at NEOGENOMICS INC, newest first. Each line links the filing it comes from. 1. 2026-07-20 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1077183/000107718326000045/neo-20260720.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NEO on TradingView](https://www.tradingview.com/symbols/NASDAQ-NEO/). ## Listing details NEOGENOMICS INC is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NEO, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: NEOGENOMICS INC - **Ticker**: NEO - **Listing**: NASDAQ - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/neogenomics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "NEOGENOMICS INC (NEO) news: offering and convertible notes", 2026-10-31, https://aibio.space/companies/neogenomics/